title: Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.
abstract: Androgen-deprivation therapy (ADT) has been reported to be active in androgen receptor (AR)-expressing, relapsed/metastatic (RM), salivary gland cancers (SGCs). Abiraterone, an inhibitor of androgen synthesis, has recently been approved as a second-line treatment in hormone-resistant (HR) prostate cancer (PCa) patients. Two patients with AR-positive HR-RM adenocarcinoma, NOS of the salivary glands have been treated with abiraterone. This is the first time that this agent has been reported to be active in tumors other than HRPCa. Immunohistochemical analysis showed overexpression of EGFR, HER2, and HER3 in both untreated primary tumors. Sequencing analysis revealed a TP53 non-functional mutation in one case and a PIK3CA-activating mutation in the other. In conclusion, second line activity of ADT in AR-expressing, adenocarcinoma, NOS of salivary glands further strengthens the pathogenic and therapeutic role of AR signaling in AR-positive SGCs.
authors.affiliation: Head and Neck Medical Oncology Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Laura D
authors.initials: LD
authors.lastname: Locati
authors.affiliation: Laboratory of Experimental Molecular Pathology; Pathology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Federica
authors.initials: F
authors.lastname: Perrone
authors.affiliation: Laboratory of Experimental Molecular Pathology; Pathology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Cortelazzi
authors.affiliation: Head and Neck Medical Oncology Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Martina
authors.initials: M
authors.lastname: Imbimbo
authors.affiliation: Head and Neck Medical Oncology Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Bossi
authors.affiliation: Radiology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Potepan
authors.affiliation: Radiology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Enrico
authors.initials: E
authors.lastname: Civelli
authors.affiliation: Medical Oncology; Azienda Policlinico Universitario Paolo Giaccone; Palermo, Italy.
authors.forename: Gaetana
authors.initials: G
authors.lastname: Rinaldi
authors.affiliation: Pathology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Quattrone
authors.affiliation: Head and Neck Medical Oncology Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Lisa
authors.initials: L
authors.lastname: Licitra
authors.affiliation: Laboratory of Experimental Molecular Pathology; Pathology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan, Italy.
authors.forename: Silvana
authors.initials: S
authors.lastname: Pilotti
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000726:Androgen Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use; D011944:Receptors, Androgen / Q000378:metabolism*; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014105:Tosyl Compounds / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D011944:Receptors, Androgen; D014105:Tosyl Compounds; D017329:Triptorelin Pamoate; C053541:bicalutamide; C089740:abiraterone
keywords: HER3; PIK3CA; TP53; abiraterone; androgen deprivation therapy; androgen receptor; salivary gland cancers